{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:06:40Z","timestamp":1773896800363,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03532-1","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T16:02:41Z","timestamp":1677340961000},"page":"2111-2118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-7770","authenticated-orcid":false,"given":"Kaname","family":"Hirowatari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"3532_CR1","doi-asserted-by":"publisher","first-page":"4647685","DOI":"10.1155\/2016\/4647685","volume":"2016","author":"T Fiseha","year":"2016","unstructured":"Fiseha T, Tamir Z (2016) Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol 2016:4647685. https:\/\/doi.org\/10.1155\/2016\/4647685","journal-title":"Int J Nephrol"},{"key":"3532_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10157-017-1385-x","volume":"21","author":"K Kosaki","year":"2017","unstructured":"Kosaki K, Kamijo-Ikemori A, Sugaya T, Tanahashi K, Kumagai H, Sawano Y, Akazawa N, Ra SG, Kimura K, Shibagaki Y, Maeda S (2017) Relationship between exercise capacity and urinary liver-type fatty acid-binding protein in middle-aged and older individuals. Clin Exp Nephrol 21:810\u2013817. https:\/\/doi.org\/10.1007\/s10157-017-1385-x","journal-title":"Clin Exp Nephrol"},{"key":"3532_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2337\/dc10-1392","volume":"34","author":"A Kamijo-Ikemori","year":"2011","unstructured":"Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K (2011) Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 34:691\u2013696. https:\/\/doi.org\/10.2337\/dc10-1392","journal-title":"Diabetes Care"},{"key":"3532_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.kint.2016.08.003","volume":"90","author":"K Matsushita","year":"2016","unstructured":"Matsushita K, Chen J, Sang Y, Ballew SH, Shimazaki R, Fukagawa M, Imai E, Coresh J, Hishida A (2016) Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int 90:1109\u20131114. https:\/\/doi.org\/10.1016\/j.kint.2016.08.003","journal-title":"Kidney Int"},{"key":"3532_CR5","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS (2014) Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311:2518\u20132531. https:\/\/doi.org\/10.1001\/jama.2014.6634","journal-title":"JAMA"},{"key":"3532_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cca.2013.05.020","volume":"424","author":"A Kamijo-Ikemori","year":"2013","unstructured":"Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T, Yasuda T, Hirata K, Kimura K (2013) Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta 424:104\u2013108. https:\/\/doi.org\/10.1016\/j.cca.2013.05.020","journal-title":"Clin Chim Acta"},{"key":"3532_CR7","doi-asserted-by":"publisher","first-page":"e54863","DOI":"10.1371\/journal.pone.0054863","volume":"8","author":"KM Chou","year":"2013","unstructured":"Chou KM, Lee CC, Chen CH, Sun CY (2013) Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. PLoS ONE 8:e54863. https:\/\/doi.org\/10.1371\/journal.pone.0054863","journal-title":"PLoS ONE"},{"key":"3532_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2478\/jomb-2019-0037","volume":"39","author":"TND Thi","year":"2020","unstructured":"Thi TND, Gia BN, Thi HLL, Thi TNC, Thanh HP (2020) Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J Med Biochem 39:224\u2013230. https:\/\/doi.org\/10.2478\/jomb-2019-0037","journal-title":"J Med Biochem"},{"key":"3532_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2337\/dc12-1298","volume":"36","author":"S-i Araki","year":"2013","unstructured":"Araki S-i, Haneda M, Koya D, Sugaya T, Isshiki K, Kume S, Kashiwagi A, Uzu T, Maegawa H (2013) Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in Type 2 diabetic patients without advanced nephropathy. Diabetes Care 36:1248\u20131253. https:\/\/doi.org\/10.2337\/dc12-1298","journal-title":"Diabetes Care"},{"key":"3532_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12933-016-0396-3","volume":"15","author":"M Sagara","year":"2016","unstructured":"Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, Aso Y (2016) Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case\u2013control study. Cardiovasc Diabetol 15:76. https:\/\/doi.org\/10.1186\/s12933-016-0396-3","journal-title":"Cardiovasc Diabetol"},{"key":"3532_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s13340-018-0376-9","volume":"10","author":"H Makino","year":"2019","unstructured":"Makino H, Matsuo M, Hishida A, Koezuka R, Tochiya M, Ohata Y, Tamanaha T, Son C, Miyamoto Y, Hosoda K (2019) Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study. Diabetol Int 10:148\u2013152. https:\/\/doi.org\/10.1007\/s13340-018-0376-9","journal-title":"Diabetol Int"},{"key":"3532_CR12","doi-asserted-by":"publisher","first-page":"e000391","DOI":"10.1136\/bmjdrc-2017-000391","volume":"5","author":"M Kitada","year":"2017","unstructured":"Kitada M, Tsuda SI, Konishi K, Takeda-Watanabe A, Fujii M, Kanasaki K, Nishizawa M, Nakagawa A, Koya D (2017) Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. BMJ Open Diabetes Res Care 5:e000391. https:\/\/doi.org\/10.1136\/bmjdrc-2017-000391","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3532_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/medicina55060268","volume":"55","author":"C Garofalo","year":"2019","unstructured":"Garofalo C, Borrelli S, Liberti ME, Andreucci M, Conte G, Minutolo R, Provenzano M, De Nicola L (2019) SGLT2 inhibitors: Nephroprotective efficacy and side effects. Medicina (Kaunas) 55:268. https:\/\/doi.org\/10.3390\/medicina55060268","journal-title":"Medicina (Kaunas)"},{"key":"3532_CR14","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/jdi.13064","volume":"10","author":"H Miyoshi","year":"2019","unstructured":"Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y (2019) Protective effect of sodium\u2013glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes. J Diabetes Investig 10:1510\u20131517. https:\/\/doi.org\/10.1111\/jdi.13064","journal-title":"J Diabetes Investig"},{"key":"3532_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0034-1395609","volume":"47","author":"A Ojima","year":"2015","unstructured":"Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S (2015) Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 47:686\u2013692. https:\/\/doi.org\/10.1055\/s-0034-1395609","journal-title":"Horm Metab Res"},{"key":"3532_CR16","doi-asserted-by":"publisher","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","volume":"8","author":"U Panchapakesan","year":"2013","unstructured":"Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2014renoprotection in diabetic nephropathy? PLoS ONE 8:e54442. https:\/\/doi.org\/10.1371\/journal.pone.0054442","journal-title":"PLoS ONE"},{"key":"3532_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G, Zhang C, Wu X (2020) SGLT2i: Beyond the glucose-lowering effect. Cardiovasc Diabetol 19:98. https:\/\/doi.org\/10.1186\/s12933-020-01071-y","journal-title":"Cardiovasc Diabetol"},{"key":"3532_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pcd.2020.10.002","volume":"15","author":"A Tumminia","year":"2021","unstructured":"Tumminia A, Graziano M, Vinciguerra F, Lomonaco A, Frittita L (2021) Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: a real-world experience. Prim Care Diabetes 15:283\u2013288. https:\/\/doi.org\/10.1016\/j.pcd.2020.10.002","journal-title":"Prim Care Diabetes"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03532-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03532-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03532-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T16:06:52Z","timestamp":1688832412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03532-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["3532"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03532-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,25]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in the studies involved human participants; hence, they were performed in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number 1103) and the 1964 Declaration of Helsinki and its later amendments. The Ethics Committees of Ishinkai Yao General Hospital approved the protocol of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}